Analysts have recently evaluated GoodRx Holdings and provided 12-month price targets. The average target is $4.16, accompanied by a high estimate of $6.00 and a low estimate of $2.75. This current ...
Eligible patients can now get the Wegovy pill — the first oral GLP-1 treatment for weight management in adults — at Hy-Vee with a GoodRx discount.
Key Insights Significant control over GoodRx Holdings by individual investors implies that the general public has ...
neffy is available in pharmacies this week and the lowest discounted cash price at retail pharmacies can be found exclusively at GoodRx neffy is the first and only needle-free treatment for Type I ...
Wrapping up Q3 earnings, we look at the numbers and key takeaways for the healthcare technology stocks, including GoodRx ...
SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today announced that the newly FDA-approved Wegovy® pill (oral semaglutide) is ...
Surescripts®, the nation’s leading health intelligence network, introduces its Patient Experience product, Script Corner™, to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results